Mucosal Adjuvants
Mucosal Adjuvants
复制标题
DOI：
10.2174/157016210791208695
复制
发表时间：
2010-06-01
影响因子：
1
通讯作者：
Medaglini, Donata
中科院分区：
文献类型：
--
作者：
Harandi, Ali M.;Medaglini, Donata
绝大多数病原体通过粘膜组织侵入身体或在粘膜组织中建立感染。开发对抗粘膜感染的疫苗是重中之重。粘膜免疫作为产生针对粘膜病原体的保护性免疫的一种手段最近引起了人们的广泛兴趣。相反，目前只有非常少的粘膜疫苗被批准用于人类使用。开发广泛的粘膜疫苗将需要开发安全有效的粘膜佐剂和递送系统。在过去的十年中，许多免疫调节剂，包括基于毒素的佐剂、Toll样受体（TLR）模拟物和非TLR靶向免疫刺激剂以及递送系统已经显示出用于实验动物中粘膜施用的前景。然而，它们在人类中的可能用途仍有待确定。本文就粘膜免疫及其佐剂的研究进展作一简要综述，重点介绍粘膜佐剂在临床应用中的研究进展。
The vast majority of pathogens invade the body through or establish infections in the mucosal tissues. Development of vaccines to combat mucosal infections represents a top priority. Mucosal immunization has recently attracted much interest as a means of generating protective immunity against mucosal pathogens. Conversely, only very few mucosal vaccines are presently approved for human use. The development of a broad range of mucosal vaccines will necessitate the development of safe and effective mucosal adjuvants and delivery systems. Over the past decade, a number of immunomodulatory agents, including toxin based adjuvants, Toll like receptor (TLR) mimetics and non TLR-targeting immunostimulators as well as delivery systems have shown promise for mucosal administration in experimental animals. However, their possible use in humans remains to be established. This paper attempts to provide a brief overview of the mucosal immunization and adjuvants with an emphasis on mucosal adjuvants in or close to clinic.